Name:	chrs_AccruedMilestonePayment
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Additional milestone payments upon achievement of certain development and regulatory milestones.

No definition available.

Name:	chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Additional milestone payments upon achievement of with subject to FDA approval

No definition available.

Name:	chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Represents co-development, regulatory and technology transfer costs.

No definition available.

Name:	chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Amount of additional clinical milestones eligible to receive

No definition available.

Name:	chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Additional payment to be made

No definition available.

Name:	chrs_CollaborationAgreementAdditionalPaymentToBeMade
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Expiration term from the effective date without providing materials that pass quality control

No definition available.

Name:	chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl
Namespace Prefix:	chrs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Maximum aggregate milestone payments to be made

No definition available.

Name:	chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds

No definition available.

Name:	chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The amount of maximum payments to be made on attainment of certain sales thresholds for each option program under the collaboration agreement.

No definition available.

Name:	chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Amount of milestone payments earned

No definition available.

Name:	chrs_CollaborationAgreementMilestonePaymentsEarned
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The amount of option exercise fee per program under the collaboration agreement.

No definition available.

Name:	chrs_CollaborationAgreementOptionExerciseFeePerProgram
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Represents the percentage of royalty on net sales under the collaboration agreement.

No definition available.

Name:	chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales
Namespace Prefix:	chrs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

Represents the percentage of royalty on net sales for each option program under the collaboration agreement.

No definition available.

Name:	chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram
Namespace Prefix:	chrs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

Period for payment of nominal research maintenance fee

No definition available.

Name:	chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee
Namespace Prefix:	chrs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Amount of regulatory milestones eligible to receive

No definition available.

Name:	chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Technical milestone payments obligated to pay

No definition available.

Name:	chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Term of agreement

No definition available.

Name:	chrs_CollaborationAgreementTerm
Namespace Prefix:	chrs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The amount of threshold payments to be made on achievement on various milestones for each option program under the collaboration agreement.

No definition available.

Name:	chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Represents costs associated to a collaboration agreement.

No definition available.

Name:	chrs_CollaborationCosts
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Represents the fair value for the discount for lack of marketability (DLOM).

No definition available.

Name:	chrs_FairValueForDiscountForLackOfMarketability
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Initial term of agreement.

No definition available.

Name:	chrs_InitialTermOfAgreement
Namespace Prefix:	chrs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Represents the maximum paid amount for co-development activities.

No definition available.

Name:	chrs_MaximumAmountPaidCoDevelopmentActivities
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Maximum antibodies partially exercised under commercialization option

No definition available.

Name:	chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption
Namespace Prefix:	chrs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Minimum antibodies to be commercialized under commercialization option

No definition available.

Name:	chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption
Namespace Prefix:	chrs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

percentage of profit shared.

No definition available.

Name:	chrs_PercentageOfGrossProfitsOnSales
Namespace Prefix:	chrs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

Percentage of option fee to be paid on partial exercise of commercialization option

No definition available.

Name:	chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption
Namespace Prefix:	chrs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

Amount of potential development milestones entitled.

No definition available.

Name:	chrs_PotentialDevelopmentMilestonesEntitled
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Represents the period before the company can sell, transfer or make any short sale of common stock.

No definition available.

Name:	chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock
Namespace Prefix:	chrs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Amount of regulatory milestones eligible to pay.

No definition available.

Name:	chrs_RegulatoryMilestonesEligibleToPay
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Amount of sales milestones entitled.

No definition available.

Name:	chrs_SalesMilestonesEntitled
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement.

No definition available.

Name:	chrs_StockPurchaseAgreementSharesAgreedToBeIssued
Namespace Prefix:	chrs_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

Value of shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement.

No definition available.

Name:	chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Represents upfront and milestone payments.

No definition available.

Name:	chrs_UpfrontAndMilestonePayment
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1

Name:	us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Price of a single share of a number of saleable stocks of a company.

No definition available.

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

Name:	us-gaap_TypeOfArrangementAxis=chrs_VaccinexLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=chrs_AdimabDevelopmentAndOptionAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=chrs_NovartisAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=chrs_GskAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	dei_LegalEntityAxis=chrs_SurfaceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_BalanceSheetLocationAxis=chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=chrs_ToripalimabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=chrs_Chs006AntiTigitAntibodyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=chrs_AntiTigitAntibodyAndIl2CytokineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: